Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 19, 2006 Brian Lawler	No Gilded Quarter for Gilead The company's recent acquisition may help it become a diversified drug giant. Investors, take note.
BusinessWeek February 19, 2007 Arlene Weintraub	How Gilead Primed The Pipeline Gilead's $2.5 billion purchase of Myogen offers instant diversification from its HIV drug focus.
The Motley Fool October 2, 2006 Brian Gorman	Gilead's Smart Risk The drug developer's latest purchase is a risk, but it's a well-calculated one. Investors, take note.
The Motley Fool December 31, 2007 Brian Lawler	Best Stock for 2008: Gilead Sciences Shares of Gilead Sciences are a good bet for next year.
The Motley Fool February 21, 2007 Brian Lawler	Gilead Closes the Gap The FDA trims Gilead's review period for a top developmental compound. Investors, take note.
The Motley Fool January 27, 2011 Brian Orelli	Gilead's Once in a Decade Quarter Gilead's revenue falls for the first time in more than a decade.
The Motley Fool June 12, 2008 Brian Lawler	Gilead's Got the Goods As long as Gilead Sciences makes good use of its cash, its long-run future looks bright.
The Motley Fool October 20, 2010 Brian Orelli	What's Your Next Trick, Gilead? Just when investors had counted Gilead Sciences down for the count, it comes roaring back.
The Motley Fool July 21, 2006 Brian Lawler	Gilead's Acquisitive Mood Trading at around 28 times 2006 EPS estimates, and with 40% growth expected for its HIV franchise, Gilead offers tempting value -- assuming it makes smart use of that cash sitting on the balance sheet.
The Motley Fool July 21, 2010 Brian Orelli	15% Revenue Growth Is Good for Pfizer, but Not Gilead Gilead needs to reaccelerate growth.
The Motley Fool July 23, 2007 Brian Lawler	Gilead's Great Growth The drugmaker announces another great quarter of growth. Investors, take note.
The Motley Fool February 27, 2007 Brian Lawler	Gilead's Green-Lighted Drug Having a diversified drug pipeline is what makes large-cap drug stocks like Gilead so enticing, even to risk-adverse investors.
The Motley Fool December 20, 2010 Brian Orelli	A Good Fit. On the Surface. Digging a little deeper into Gilead's acquisition of Arresto.
The Motley Fool February 23, 2010 Brian Orelli	The One That Didn't Get Away After some encouragement, the FDA approves Gilead's Cayston.
The Motley Fool December 16, 2009 Brian Orelli	Gilead's Phase 3 Train Wreck Gilead Sciences' darusentan looked so promising.
The Motley Fool July 16, 2011 Melly Alazraki	HIV Studies May Not Mean Much to Gilead Studies find Gilead drugs can help prevent HIV infections, but that may not help sales.
The Motley Fool July 27, 2011 Brian Orelli	Not Hypergrowth, but Good Enough Gilead posts a double-digit revenue gain.
The Motley Fool May 19, 2004 Roger Nusbaum	Gilead Shines This biotech company looks strong because investors can relate to its products.
The Motley Fool July 18, 2008 Brian Lawler	Still Liking Gilead, Warts and All Don't look past a few issues, even though Gilead still has a bright future.
The Motley Fool September 6, 2007 Brian Lawler	Foolish Fantasy Football: Gilead Sciences on Offense For his fantasy football investment team, this stock analyst thinks Gilead packs enough offensive muscle to score in anyone's portfolio.
The Motley Fool April 22, 2009 Brian Orelli	Better Than Recession-Proof The whole health-care industry may not be recession-proof, but Gilead has shown that the right combination of drugs can lead to stellar returns -- even in a down economy.
The Motley Fool May 30, 2008 Brian Lawler	Gilead Gets Synergistic Gilead Sciences newly acquired compound will play nicely with the drugmaker's existing products.
The Motley Fool June 18, 2007 Brian Lawler	Gilead Gets the Payoff Gilead gets marketing approval for one of its drug candidates. Investors, take note.
The Motley Fool March 29, 2010 Brian Orelli	5 Drugmakers Producing Cash for You Take greenbacks over earnings any day.
The Motley Fool May 24, 2011 Brian Orelli	J&J Approved, but Needs Help From a Friend The HIV combo product is the key.
The Motley Fool January 27, 2010 Brian Orelli	The Virus-Killer's Killer Quarter Gilead Sciences closed out 2009 with a solid 42% increase in revenue in the fourth quarter, thanks to its HIV drugs.
The Motley Fool June 25, 2010 Brian Orelli	Diversification Times 50,000 Gilead Sciences diversifies any way it can.
The Motley Fool July 30, 2004 Roger Nusbaum	Gilead Keeps Rolling Along Biotech can be a tough place to invest, but Gilead Sciences offers relative stability.
The Motley Fool February 22, 2008 Brian Lawler	The Hypertension Fight Expands News from the pharmaceutical industry regarding hypertension medications: Gilead and Glaxo win E.U. approval for a drug, and Encysive's sellout came just in time.
Pharmaceutical Executive September 1, 2010	Is There a Balm for Gilead? A new leader, a big acquisition, and a bold investment in HIV may all be in the works at Gilead. But what will it take to restore the glory days?
The Motley Fool September 19, 2008 Brian Lawler	FDA Tells Gilead to Take 1 More Step There's a small consolation prize for Gilead Sciences in this rejection from the FDA.
The Motley Fool February 23, 2011 Brian Orelli	Gilead Gears Up to Fight Cancer Gilead has been infected by the diversification bug.
The Motley Fool March 31, 2011 Brian Orelli	Gilead's Long-Term Cancer Fight An academic partnership is a good sign it's serious.
The Motley Fool January 6, 2010 Brian Orelli	Gilead Goes It Alone ... for Now Investors jump for joy as Gilead Sciences announces what on the surface sounds like rather inconsequential data.
The Motley Fool April 28, 2011 Brian Orelli	Victory for Victrelis Merck's hepatitis C drug moves one step closer to FDA approval.
The Motley Fool March 31, 2011 Brian Orelli	Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good.
BusinessWeek September 18, 2006 Gene G. Marcial	Gilead Has "Room To Run" Most pharmaceutical companies are limping, but Gilead Sciences has sprinted.
The Motley Fool January 25, 2008 Brian Lawler	What's Not to Like About Gilead? Gilead is looking more and more like a diversified pharma with a robust clinical-stage pipeline and growing cash flows.
The Motley Fool October 21, 2009 Brian Orelli	Double-Digit Growth in a Recession The strong double-digit growth at Gilead shouldn't be much of a surprise; HIV patients need their medication even in a recession.
The Motley Fool April 22, 2011 Sean Williams	Pharma's Most Perilous Pipelines Patent expirations expose weaknesses for these Wall Street darlings.
The Motley Fool July 12, 2011 Tracy Staton	Gilead First to Jump Into AIDS Patent Pool Gilead Sciences has broken the ice on the AIDS drug patent pool.
The Motley Fool August 20, 2007 Brian Lawler	Are These Perfect Pharma Acquisitions? Weighing recent drug-industry deals' odds of success: AstraZeneca and MedImmune... Shire and New River Pharmaceuticals... Gilead and Myogen...
The Motley Fool June 30, 2010 Brian Orelli	Which Midsized Biotech Is the Best Buy? Biogen Idec, Amgen, or Gilead? Which of these biotechs has the most potential for growth?
The Motley Fool January 21, 2011 Brian Orelli	Mark Your Calendar, Drug Investors Vertex announces that the Food and Drug Administration has accepted its New Drug Application to market telaprevir.
The Motley Fool April 24, 2007 Brian Lawler	Gilead's Sales Are Galloping Ahead The biotech giant announces first-quarter financial results, with its most important drugs showing no weakness. What's important for investors to figure out is whether the valuation on shares of Gilead needs to shrink or expand in order to meet its future financial fortunes.
The Motley Fool August 9, 2011 Brian Orelli	Some Potential Good News in Biotech The FDA should approve Gilead's Btripla.
The Motley Fool November 30, 2010 Brian Orelli	A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.
The Motley Fool April 19, 2006 John Bluis	Gilead's Got Cash Up to the Gills The pharmaceutical cashes in on bird-flu fears. The company's strong performance means that investors have to pay a slight premium for its shares.
The Motley Fool October 7, 2011 Brian Orelli	A Little Help, Please Gilead pumps up the pipeline.
The Motley Fool July 30, 2010 Brian Orelli	A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs.